Eisai's Zebinix shown to be effective and well-tolerated

Once-daily Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai (TYO: 4523) is effective, retained and well-tolerated when given as an add-on to anti-epileptic monotherapy to adults in routine clinical practice, according to new data.

The results of an interim analysis of the non-interventional EPOS (Eslicarbazepine acetate in Partial-Onset Seizure) study, presented at the 21st European Congress on Epileptology (ECE) in Stockholm, Sweden, focus on eslicarbazepine acetate, a novel anti-epilepsy treatment for adult individuals with partial epilepsy, targets sodium channels, stabilizing their inactive state. It is indicated as adjunctive therapy in adults with partial onset seizures, with or without secondary generalization.

The aim of the EPOS study was to assess retention rate, effectiveness, safety and tolerability of eslicarbazepine acetate as the only add-on to monotherapy in a real world clinical setting in eight European countries (UK, Ireland, Denmark, Sweden, Norway, France, Czech Republic and Germany).